Dr. Reddy’s Laboratories Ltd ADR (RDY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Dr. Reddy’s Laboratories Ltd ADR (RDY) has a cash flow conversion efficiency ratio of 0.029x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($10.91 Billion) by net assets ($375.76 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Dr. Reddy’s Laboratories Ltd ADR for the company's overall valuation and market capitalisation.
Dr. Reddy’s Laboratories Ltd ADR - Cash Flow Conversion Efficiency Trend (2000–2025)
This chart illustrates how Dr. Reddy’s Laboratories Ltd ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Dr. Reddy’s Laboratories Ltd ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dr. Reddy’s Laboratories Ltd ADR ranked by their cash flow conversion efficiency. Explore Dr. Reddy’s Laboratories Ltd ADR cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
HDFC Asset Management Company Limited
NSE:HDFCAMC
|
0.130x |
|
JAMES HARDIE INDUST.ADR/1
F:JHA0
|
N/A |
|
Pinterest Inc
NYSE:PINS
|
0.067x |
|
Hero MotoCorp Limited
NSE:HEROMOTOCO
|
0.164x |
|
Shenzhen Envicool Technology Co Ltd
SHE:002837
|
-0.024x |
|
Rentokil Initial PLC
NYSE:RTO
|
0.091x |
|
Zebra Technologies Corporation
NASDAQ:ZBRA
|
0.051x |
|
Carrefour SA
PA:CA
|
-0.055x |
Annual Cash Flow Conversion Efficiency for Dr. Reddy’s Laboratories Ltd ADR (2000–2025)
The table below shows the annual cash flow conversion efficiency of Dr. Reddy’s Laboratories Ltd ADR from 2000 to 2025. View RDY live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $337.17 Billion | $46.43 Billion | 0.138x | -14.97% |
| 2024-03-31 | $280.55 Billion | $45.43 Billion | 0.162x | -36.46% |
| 2023-03-31 | $230.99 Billion | $58.87 Billion | 0.255x | +72.76% |
| 2022-03-31 | $190.53 Billion | $28.11 Billion | 0.148x | -99.02% |
| 2021-03-31 | $2.37 Billion | $35.70 Billion | 15.083x | +3.55% |
| 2020-03-31 | $2.05 Billion | $29.84 Billion | 14.566x | +7014.23% |
| 2019-03-31 | $140.20 Billion | $28.70 Billion | 0.205x | +43.61% |
| 2018-03-31 | $126.46 Billion | $18.03 Billion | 0.143x | -17.80% |
| 2017-03-31 | $124.04 Billion | $21.51 Billion | 0.173x | -46.04% |
| 2016-03-31 | $128.34 Billion | $41.25 Billion | 0.321x | +42.90% |
| 2015-03-31 | $111.30 Billion | $25.03 Billion | 0.225x | +4.93% |
| 2014-03-31 | $90.80 Billion | $19.46 Billion | 0.214x | +1076.68% |
| 2013-03-31 | $731.04 Billion | $13.32 Billion | 0.018x | -93.52% |
| 2012-03-31 | $57.44 Billion | $16.15 Billion | 0.281x | +61.44% |
| 2011-03-31 | $45.99 Billion | $8.01 Billion | 0.174x | -43.49% |
| 2010-03-31 | $42.91 Billion | $13.23 Billion | 0.308x | +187.63% |
| 2009-03-31 | $42.05 Billion | $4.50 Billion | 0.107x | -17.63% |
| 2008-03-31 | $47.07 Billion | $6.12 Billion | 0.130x | -54.17% |
| 2007-03-31 | $41.69 Billion | $11.83 Billion | 0.284x | +283.73% |
| 2006-03-31 | $22.27 Billion | $1.65 Billion | 0.074x | -32.37% |
| 2005-03-31 | $20.95 Billion | $2.29 Billion | 0.109x | -42.46% |
| 2004-03-31 | $21.08 Billion | $4.01 Billion | 0.190x | -18.03% |
| 2003-03-31 | $18.78 Billion | $4.35 Billion | 0.232x | -22.97% |
| 2002-03-31 | $15.44 Billion | $4.65 Billion | 0.301x | +156.40% |
| 2001-03-31 | $5.24 Billion | $614.87 Million | 0.117x | -17.97% |
| 2000-03-31 | $99.87 Million | $14.29 Million | 0.143x | -- |
About Dr. Reddy’s Laboratories Ltd ADR
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical pr… Read more